Association Analysis between Maternal Serum Biomarkers and Fetal Congenital Heart Disease
DOI:
https://doi.org/10.59958/hsf.6703Keywords:
congenital heart disease, Down's screening, alpha fetal protein, human chorionic gonadotropin, unconjugated estriol 3Abstract
Objective: To investigate the association of maternal serum biomarkers alpha fetal protein (AFP), β-human chorionic gonadotropin (HCG) and unconjugated estriol 3 (uE3) in the second trimester with fetal congenital heart disease (CHD) in low risk populations during the screening of Down's syndrome. Methods: 109 cases diagnosed with fetal CHD in the second trimester by fetal echocardiography were enrolled as the CHD group. Pregnancy- and gestational-age matched 344 cases without fetal CHD were used as the control group. The values of maternal serum biomarkers HCG, AFP and uE3 were tested and the association with CHD was analyzed. Results: The means of HCG multiple of median (MoM) and AFP MoM were higher, while the mean of uE3 MoM was lower in the CHD group than those of the control group (p < 0.05). The number of cases with HCG MoM ≥85% quantile, AFP MoM ≥85% quantile was more, while that with uE3 MoM ≤15% quantile was less in the CHD group than that of the control group (p < 0.05). The univariate logistic regression analysis showed that fetal CHD was associated with high values of HCG MoM and AFP MoM and low value of uE3 MoM as well as the HCG MoM ≥85% quantile, AFP MoM ≥85% quantile and the uE3 MoM ≤15% quantile. The multivariate logistic regression analysis showed that HCG MoM ≥85% quantile and AFP MoM ≥85% quantile or the uE3 ≤15% quantile were the independent factors of fetal CHD. In addition, the risk of fetal CHD was higher when one situation existed among the HCG MoM ≥85% quantile, AFP MoM ≥85% quantile and the uE3 MoM ≤15% quantile. The risk of fetal CHD was much higher when both the HCG MoM ≥85% quantile and AFP MoM ≥85% quantile existed or both the HCG MoM ≥85% quantile and the uE3 MoM existed ≤15% quantile. Conclusions: Second trimester maternal serum biomarkers may be useful indicators for fetal evaluation for CHD to screen positive pregnancies without identified chromosomal defects.
References
Zhang YF, Zeng XL, Zhao EF, Lu HW. Diagnostic Value of Fetal Echocardiography for Congenital Heart Disease: A Systematic Review and Meta-Analysis. Medicine. 2015; 94: e1759.
Liu H, Zhou J, Feng Q, Gu H, Wan G, Zhang H, et al. Fetal echocardiography for congenital heart disease diagnosis: a meta-analysis, power analysis and missing data analysis. European Journal of Preventive Cardiology. 2015; 22: 1531–1547.
Yang L, Pei Q, Li Y, Yang Z. The Application of an Anatomical Database for Fetal Congenital Heart Disease. Chinese Medical Journal. 2015; 128: 2583–2587.
Aviram A, Jones SL, Huang T, Satkunaratnam A, Melamed N, Mei-Dan E. Reassurance from second trimester sonographic placental scan for pregnancies complicated by abnormal first trimester biomarkers. The Journal of Maternal-Fetal and Neonatal Medicine. 2022; 35: 9415–9421.
Bravo-valenzuela NJ, Peixoto AB, Araujo Júnior E. Prenatal diagnosis of congenital heart disease: a review of current knowledge. Indian Heart Journal. 2018; 70: 150–164.
Desgrosellier JS, Mundell NA, McDonnell MA, Moses HL, Barnett JV. Activin receptor-like kinase 2 and Smad6 regulate epithelial–mesenchymal transformation during cardiac valve formation. Developmental Biology. 2005; 280: 201–210.
Jelliffe-Pawlowski LL, Walton-Haynes L, Currier RJ. Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results. American Journal of Medical Genetics Part A. 2008; 146A: 2455–2467.
Ministry of Health P. Report on the prevention and treatment of birth defects in China. Chinese Contemporary Medicine. 2012; 19: 1–5.
Cardiac screening examination of the fetus: guidelines for performing the ‘basic' and ‘extended basic' cardiac scan. Ultrasound in Obstetrics and Gynecology. 2006; 27: 107–113.
Bowen Z. Prenatal ultrasound guidelines - Fetal heart echocardiography guidelines. Chinese Journal of Ultrasonography. 2011; 20: 904–909.
DeVore GR. Trisomy 21: 91% detection rate using second-trimester ultrasound markers. Ultrasound in Obstetrics and Gynecology. 2000; 16: 133–141.
Souter VL, Nyberg DA, El-Bastawissi A, Zebelman A, Luthhardt F, Luthy DA. Correlation of ultrasound findings and biochemical markers in the second trimester of pregnancy in fetuses with trisomy 21. Prenatal Diagnosis. 2002; 22: 175–182.
Jelliffe-Pawlowski L, Baer R, Moon-Grady AJ, Currier RJ. Second trimester serum predictors of congenital heart defects in pregnancies without chromosomal or neural tube defects. Prenatal Diagnosis. 2011; 31: 466–472.
Jelliffe-Pawlowski LL, Walton-Haynes L, Currier RJ. Identification of second trimester screen positive pregnancies at increased risk for congenital heart defects. Prenatal Diagnosis. 2009; 29: 570–577.
Kiran T, Bethel J, Bhal P. Correlation of abnormal second trimester maternal serum alpha-fetoprotein (MSAFP) levels and adverse pregnancy outcome. Journal of Obstetrics and Gynaecology. 2005; 25: 253–256.
Ganapathy R, Lamont RF, Bassett P. Unexplained elevated maternal serum beta-HCG concentration and adverse pregnancy outcome. Prenatal Diagnosis. 2007; 27: 995–999.
Malik S, Cleves MA, Zhao W, Correa A, Hobbs CA, National Birth Defects Prevention Study. Association between Congenital Heart Defects and Small for Gestational Age. Pediatrics. 2007; 119: e976–e982.
Barkehall-thomas A, Tong S, Baker LS, Edwards A, Wallace EM. Maternal serum activin a and the prediction of intrauterine growth restriction. The Australian and New Zealand Journal of Obstetrics and Gynaecology. 2006; 46: 97–101.
Salameh M, Lee J, Palomaki G, Eklund E, Curran P, Suarez JAR, et al. Snoring and markers of fetal and placental wellbeing. Clinica Chimica Acta. 2018; 485: 139–143.
Hematian MN, Hessami K, Torabi S, Saleh M, Nouri B, Saleh M. A prospective cohort study on association of first-trimester serum biomarkers and risk of isolated foetal congenital heart defects. Biomarkers. 2021; 26: 747–751.
Gkogkos P, Androutsopoulos G, Vassilakos P, Panayiotakis G, Kourounis G, Decavalas G. Mid-trimester maternal serum AFP levels in predicting adverse pregnancy outcome. Clinical and Experimental Obstetrics and Gynecology. 2008; 35: 208–210.
